AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. Co. focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). Co.'s pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. The ACIU average annual return since 2016 is shown above.
The Average Annual Return on the ACIU average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ACIU average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACIU average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ACIU Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
